Carlsson J, Tebbe U, Rox J, Harmjanz D, Haerten K, Neuhaus K L, Seidel F, Niederer W, Miketić S
Medizinische Klinik II, Klinikum Lippe-Detmold, Germany.
Am J Cardiol. 1996 Dec 15;78(12):1380-4. doi: 10.1016/s0002-9149(96)00647-9.
The purpose of this investigation was to define cardioversion success rates, frequency of complications of cardioversion, and current treatment practices in elderly patients (aged > or = 65 years) with atrial fibrillation (AF). The results were compared with those in younger patients (aged < 65 years). The investigation was a prospective multicenter observational study with 61 participating cardiology clinics. Consecutive patients in whom cardioversion of AF was planned had to be prospectively registered. Of 1,152 patients registered, 570 (49.5%) were < 65 years old (group 1) and 582 (50.5%) were > or = 65 years (group 2). The overall success rate of cardioversion on an intention-to-treat basis was 76.1% in group 1 and 72.7% in group 2 (p = 0.18). In multivariate analysis, left atrial size and New York Heart Association functional class before cardioversion were identified as predictors of success (p < 0.001, respectively; p = 0.025). These clinical factors were not equally distributed between the age groups: Left atrial size was larger in the elderly than in younger patients (44.0 +/- 6.4 mm vs 42.8 +/- 6.4 mm; p = 0.006) and a New York Heart Association functional class > or = II was more prevalent in group 2 than in group 1 (48.6% vs 29.6%; p < 0.001). The overall complication rates were not significantly different between the 2 groups (4.2% in group 1 vs 5.3% in group 2; p = 0.37). The frequency of patients who were adequately anticoagulated for cardioversion was 56.9% in age group 1 and 39.6% in age group 2 (p < 0.001). In chronic AF the same trend for age-dependent underuse of anticoagulation was observed. Age itself was not a predictor of cardioversion success and did not predispose to higher complication rates. Therefore, cardioversion should be considered in older patients with the same criteria and emphasis as in younger patients. Anticoagulation and antithrombotic medication is underused for cardioversion and in treating chronic AF, especially in elderly patients.
本研究的目的是确定老年(年龄≥65岁)心房颤动(AF)患者的复律成功率、复律并发症发生率及当前的治疗方法。并将结果与年轻患者(年龄<65岁)进行比较。该研究是一项前瞻性多中心观察性研究,有61家参与的心脏病诊所。计划进行房颤复律的连续患者需进行前瞻性登记。在登记的1152例患者中,570例(49.5%)年龄<65岁(第1组),582例(50.5%)年龄≥65岁(第2组)。在意向性治疗基础上,第1组复律的总体成功率为76.1%,第2组为72.7%(p = 0.18)。多变量分析显示,复律前左心房大小和纽约心脏协会心功能分级是成功的预测因素(分别为p <0.001;p = 0.025)。这些临床因素在年龄组间分布不均:老年患者的左心房大小大于年轻患者(44.0±6.4mm对42.8±6.4mm;p = 0.006),纽约心脏协会心功能分级≥II级在第2组比第1组更常见(48.6%对29.6%;p <0.001)。两组的总体并发症发生率无显著差异(第1组为4.2%,第2组为5.3%;p = 0.37)。复律时充分抗凝的患者比例在年龄组1中为56.9%,在年龄组2中为39.6%(p <0.001)。在慢性房颤中也观察到了年龄依赖性抗凝使用不足的相同趋势。年龄本身不是复律成功的预测因素,也不会导致更高的并发症发生率。因此,对于老年患者,应与年轻患者一样,依据相同标准并给予同等重视来考虑复律。抗凝和抗血栓药物在复律及治疗慢性房颤时使用不足,尤其是在老年患者中。